Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 20.66M | 22.93M | 729.00K | 21.26M | 20.18M |
| Gross Profit | -20.66M | -22.93M | -729.00K | -21.26M | -20.18M |
| SG&A Expenses | 7.43M | 7.31M | 5.75M | 5.31M | 6.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.09M | 30.23M | 29.50M | 26.58M | 26.18M |
| Operating Income | -28.09M | -30.23M | -29.50M | -26.58M | -26.18M |
| Income Before Tax | -20.94M | -39.20M | -56.66M | -31.90M | -25.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.94M | -39.20M | -56.66M | -31.90M | -25.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.94M | -39.20M | -56.66M | -31.90M | -25.11M |
| EBIT | -28.09M | -30.23M | -29.50M | -26.58M | -26.18M |
| EBITDA | -26.28M | -28.42M | -27.72M | -24.79M | -24.35M |
| EPS Basic | -0.16 | -0.33 | -0.48 | -0.29 | -0.24 |
| Normalized Basic EPS | -0.13 | -0.16 | -0.16 | -0.16 | -0.16 |
| EPS Diluted | -0.16 | -0.33 | -0.48 | -0.29 | -0.24 |
| Normalized Diluted EPS | -0.13 | -0.16 | -0.16 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 126.98M | 119.41M | 119.17M | 108.25M | 103.61M |
| Average Diluted Shares Outstanding | 126.98M | 119.41M | 119.17M | 108.25M | 103.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |